The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer Tadaaki Taniguchi said.

AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from ... Revolution Medicines, Quanta Therapeutics, and Roche/Chugai. Mirati’s MRTX1133 is in phase ...

Amgen reported yesterday that full-year 2023 sales of Lumakras were $280 million, a dip on the prior year, while Mirati ... KRAS category comes shortly after AstraZeneca licensed a KRAS G12D ...

which bear the KRAS G12D or G12V mutation (approximately 70% of pancreatic cancer patients). Overall the updated analysis reveals a 56 LONDON, September 09, 2024--Silexion Therapeutics (NASDAQ ...

BOSTON, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq ... target patient population (KRAS-mutated pancreatic adenocarcinoma) and the primary study endpoint of disease ...

On Tuesday, Silexion Therapeutics Corp. (NASDAQ ... SIL-204 inhibits key oncogenic KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D. Intratumoral administration of SIL-204 microparticles ...

Silexion Therapeutics (SLXN ... SIL-204 inhibits key oncogenic KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D. Intratumoral administration of SIL-204 microparticles reduced tumor ...

The company is exploring how this promising data can inform an expanded next-generation treatment strategy for KRAS-driven cancers. It expects to announce details of its expanded development plan ...

On Tuesday, Silexion Therapeutics Corp. (NASDAQ ... SIL-204 inhibits key oncogenic KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D. Intratumoral administration of SIL-204 microparticles ...